Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107520 · ClinicalTrials.gov registry record · Early Phase 1
Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH
A Early Phase 1 study of Developmental Dysplasia of the Hip, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT03107520: Recruiting Early Phase 1 study of Developmental Dysplasia of the Hip, sponsored by Children's Hospital of Philadelphia.
NCT03107520 is a Early Phase 1 study of Developmental Dysplasia of the Hip that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 125 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (136% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03107520, a Early Phase 1 study of Developmental Dysplasia of the Hip, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.
Primary Outcome
The visualization of epiphyseal vascularity on the sonogram from intraoperative CEUS will be assessed by a trained sonographer and musculoskeletal radiologist administering the CEUS and reviewing the images.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Intraoperative contrast-enhanced ultrasound (CEUS)
- DRUG Lumason
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2030-04 |
| Phase | Early Phase 1 |
What NCT03107520 shows while recruiting
NCT03107520 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (136% higher).
The record links to 1 condition, with Developmental Dysplasia of the Hip appearing as the primary indexed condition, and to 2 interventions - of which Intraoperative contrast-enhanced ultrasound (CEUS) is the first listed.
NCT03107520 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03107520 about?
NCT03107520 is a clinical study titled "Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH". This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.
What is the current status of trial NCT03107520?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 125 participants. The study started on 2017-05-22. Estimated completion is 2030-04.
What conditions does trial NCT03107520 study?
This clinical trial studies the following conditions: Developmental Dysplasia of the Hip.
What interventions are being tested in trial NCT03107520?
The interventions under investigation include: Intraoperative contrast-enhanced ultrasound (CEUS) (DIAGNOSTIC_TEST), Lumason (DRUG).
Who is sponsoring clinical trial NCT03107520?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03107520 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03107520's enrollment target sits among peer trials
125 143rd of 2000 higher than 1,857 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI